Family Management Corp lowered its stake in Amgen, Inc. (NASDAQ:AMGN) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,956 shares of the medical research company’s stock after selling 1,047 shares during the quarter. Amgen makes up approximately 2.8% of Family Management Corp’s investment portfolio, making the stock its 10th largest position. Family Management Corp’s holdings in Amgen were worth $4,759,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AMGN. FMR LLC increased its position in shares of Amgen by 4.4% in the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares during the last quarter. Natixis increased its position in shares of Amgen by 2,612.1% in the second quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after acquiring an additional 510,281 shares during the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Amgen by 54.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock valued at $222,847,000 after acquiring an additional 380,562 shares during the last quarter. O Shaughnessy Asset Management LLC increased its position in shares of Amgen by 404.6% in the third quarter. O Shaughnessy Asset Management LLC now owns 456,500 shares of the medical research company’s stock valued at $94,333,000 after acquiring an additional 366,027 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Amgen by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after acquiring an additional 343,690 shares during the last quarter. 76.94% of the stock is currently owned by institutional investors and hedge funds.

In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.

AMGN has been the topic of a number of recent research reports. Cann reaffirmed a “buy” rating and issued a $224.00 target price on shares of Amgen in a research report on Monday, October 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $220.00 target price on shares of Amgen in a research report on Monday, October 1st. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Monday, October 1st. Oppenheimer reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Finally, BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a research report on Wednesday, September 26th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Amgen currently has an average rating of “Hold” and a consensus price target of $205.68.

Shares of NASDAQ AMGN opened at $191.44 on Friday. The company has a market cap of $126.81 billion, a price-to-earnings ratio of 15.22, a price-to-earnings-growth ratio of 2.07 and a beta of 1.41. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08. Amgen, Inc. has a twelve month low of $163.31 and a twelve month high of $210.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. During the same quarter in the previous year, the company posted $3.27 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. On average, analysts anticipate that Amgen, Inc. will post 14.24 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.03%. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s payout ratio is currently 41.97%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/12/08/amgen-inc-amgn-shares-sold-by-family-management-corp.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.